← Back to patent-cliff list
Tacrolimus (VIVUS)
Tier C — Watch / tradeTacrolimus (VIVUS)
Selten Pharma
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BMPR2, Cytokines, Calcineurin
Indications (approved)：Pulmonary arterial hypertension
Regional status
US
Phase II
2024-01-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tacrolimus (VIVUS)?
Approved indications include: Pulmonary arterial hypertension.
When does the Tacrolimus (VIVUS) patent expire?
No public expiry year is available for Tacrolimus (VIVUS) yet; this page updates once verified.
How do I get a quote for Tacrolimus (VIVUS) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29